Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab Extension in Generalized Myasthenia Gravis
NCT05716035Phase 3Recruiting
- Sponsor
- Tangdu Hospital
- Start
- Apr 2023
- Primary completion
- Jul 2024
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 3 trial of tocilizumab in myasthenia gravis (MG), sponsored by Tangdu Hospital. Started Apr 2023; status: recruiting.
02
Drugs
tocilizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT05716035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05716035.